Last reviewed · How we verify

Intravenous brivaracetam

Muhammad Aamir Latif · Phase 1 active Small molecule

Intravenous brivaracetam is a Small molecule drug developed by Muhammad Aamir Latif. It is currently in Phase 1 development.

At a glance

Generic nameIntravenous brivaracetam
SponsorMuhammad Aamir Latif
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intravenous brivaracetam

What is Intravenous brivaracetam?

Intravenous brivaracetam is a Small molecule drug developed by Muhammad Aamir Latif.

Who makes Intravenous brivaracetam?

Intravenous brivaracetam is developed by Muhammad Aamir Latif (see full Muhammad Aamir Latif pipeline at /company/muhammad-aamir-latif).

What development phase is Intravenous brivaracetam in?

Intravenous brivaracetam is in Phase 1.

Related